Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Chessell

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Brain Communications|September 12, 2025
Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50Craig Shering, Michael Pomfret, Robert J Kubiak, et al.
Pain|January 20, 2018
Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic painLouise S C Nicol, Peter Thornton, Jon P Hatcher, et al.
Brain : a Journal of Neurology|March 4, 2025
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraineCaroline M Kopruszinski, John E Linley, Peter Thornton, et al.
Annals of Clinical and Translational Neurology|March 27, 2019
Anti-PrP<sup>C</sup> antibody rescues cognition and synapses in transgenic alzheimer miceTimothy O Cox, Erik C Gunther, A Harrison Brody, et al.
Neuroscience Letters|April 23, 2013
Artemin-GFRα3 interactions partially contribute to acute inflammatory hypersensitivityPeter Thornton, Jon P Hatcher, Ian Robinson, et al.
EMBO Molecular Medicine|September 1, 2017
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variantPeter Thornton, Jean Sevalle, Michael J Deery, et al.
BMJ Open|March 25, 2019
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's diseaseIvan Koychev, Jennifer Lawson, Tharani Chessell, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2004
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitorsPaul Beswick, Sharon Bingham, Chas Bountra, et al.
Annals of the New York Academy of Sciences|May 9, 2012
Understanding chronic inflammatory and neuropathic painJane P Hughes, Iain Chessell, Richard Malamut, et al.
Pain|May 3, 2019
Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic painWendy A Williams, John E Linley, Clare A Jones, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Brain Communications|September 12, 2025
Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50Craig Shering, Michael Pomfret, Robert J Kubiak, et al.
Pain|January 20, 2018
Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic painLouise S C Nicol, Peter Thornton, Jon P Hatcher, et al.
Brain : a Journal of Neurology|March 4, 2025
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraineCaroline M Kopruszinski, John E Linley, Peter Thornton, et al.
Annals of Clinical and Translational Neurology|March 27, 2019
Anti-PrP<sup>C</sup> antibody rescues cognition and synapses in transgenic alzheimer miceTimothy O Cox, Erik C Gunther, A Harrison Brody, et al.
Neuroscience Letters|April 23, 2013
Artemin-GFRα3 interactions partially contribute to acute inflammatory hypersensitivityPeter Thornton, Jon P Hatcher, Ian Robinson, et al.
EMBO Molecular Medicine|September 1, 2017
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variantPeter Thornton, Jean Sevalle, Michael J Deery, et al.
BMJ Open|March 25, 2019
Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's diseaseIvan Koychev, Jennifer Lawson, Tharani Chessell, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2004
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitorsPaul Beswick, Sharon Bingham, Chas Bountra, et al.
Annals of the New York Academy of Sciences|May 9, 2012
Understanding chronic inflammatory and neuropathic painJane P Hughes, Iain Chessell, Richard Malamut, et al.
Pain|May 3, 2019
Antibodies binding the head domain of P2X4 inhibit channel function and reverse neuropathic painWendy A Williams, John E Linley, Clare A Jones, et al.
Pageof 3